CCR5-Delta32, ACE2, TMPRSS2, and Host Viral Entry Genetics

CCR5-Delta32, ACE2, TMPRSS2, and IFITM3 exemplify how genetic variation in human host-cell surface receptors, proteolytic priming enzymes, and endosomal restriction factors controls viral tropism, pandemic susceptibility, and antiviral drug discovery. Because obligate intracellular viruses depend on specific host-encoded macromolecular locks and keys to bind the plasma membrane, trigger glycoprotein conformational changes, and fuse their lipid envelopes with host bilayers, naturally occurring human loss-of-function or splice-altering alleles in these entry factors create marked differences in clinical infection outcomes across populations.

Three canonical host-entry systems illustrate this evolutionary coevolution: first, the 32-bp coding deletion in C-C chemokine receptor type 5 (CCR5-Δ32, rs333 on chromosome 3p21.31), which abolishes cell-surface expression of the mandatory co-receptor for R5-tropic human immunodeficiency virus type 1 (HIV-1), conferring homozygous resistance to HIV-1 infection and inspiring both the allosteric antagonist maraviroc and curative hematopoietic stem-cell transplants; second, the pairing of angiotensin-converting enzyme 2 (ACE2 on ChrXp22.2) with transmembrane protease, serine 2 (TMPRSS2 on Chr21q22.3), which mediates spike (S) binding and S2′ fusion-peptide cleavage for SARS-CoV-2 and SARS-CoV-1; and third, interferon-induced transmembrane protein 3 (IFITM3 on the subtelomere of Chr11p15.5), an amphipathic endosomal protein that blocks lipid hemifusion of influenza A and coronaviruses (impaired by the common splice-altering variant rs12252-C).

Sequential CD4–gp120–CCR5 Engagement and gp41 Six-Helix Bundle Fusion

Encoded within the C-C chemokine receptor gene cluster (CCR9–CXCR6–XCR1–CCR1–CCR3–CCR2–CCR5) on chromosome 3p21.31, CCR5 is a 352-amino-acid, seven-transmembrane (7TM) Class A G-protein-coupled receptor (Gα_i-coupled) expressed on memory CD4⁺ CCR5⁺ T lymphocytes, macrophages, microglia, and mucosal dendritic cells (responding physiologically to the β-chemokines RANTES/CCL5, MIP-1α/CCL3, and MIP-1β/CCL4).

To infect a mucosal CD4⁺ T cell or macrophage during sexual or parenteral transmission, R5-tropic (M-tropic) HIV-1—which accounts for >95% of all transmitted/founder HIV-1 strains—must execute a two-step receptor-co-receptor cascade mediated by its trimeric envelope (Env) spike (gp120/gp41):

1. Primary CD4 Binding and V3 Loop Exposure: The gp120 surface subunit first binds the D1 immunoglobulin domain of CD4, triggering a structural rearrangement (bridging sheet formation) that exposes the hypervariable third variable loop (V3 loop) of gp120.
2. Co-Receptor CCR5 Docking and gp41 Fusion: The sulfated tyrosine residues (Tyr10, Tyr14, Tyr15) at the N-terminus of CCR5 dock onto the base of the gp120 V3 stem, while the crown of the V3 loop inserts into the 7TM orthosteric pocket (second extracellular loop ECL2) of CCR5. Only upon CCR5 engagement does the transmembrane gp41 subunit spring its hydrophobic fusion peptide into the T-cell plasma membrane and fold its heptad repeats (HR1 and HR2) into a thermostable six-helix bundle (6-HB) that fuses the viral and host membranes (whereas late-stage X4-tropic HIV-1 variants mutate the V3 loop to use CXCR4 on naive T cells).

The 32-bp Frameshift Deletion (CCR5-Δ32), Maraviroc, and Stem-Cell Cures

In 1996, analysis of multiply exposed yet persistently uninfected individuals (EU cohorts) revealed that homozygotes (Δ32/Δ32) for a 32-base-pair deletion (rs333, c.554_585del32) within the single coding exon of CCR5 enjoy near-complete resistance to R5-tropic HIV-1 infection, while WT/Δ32 heterozygotes exhibit ~50% lower cell-surface CCR5 density, 0.5–0.8 log₁₀ lower viral load set-points, and a 2- to 4-year delay in progression to AIDS. At the molecular level, deleting nucleotides 554–585 (corresponding to the second extracellular loop ECL2 between TM4 and TM5) shifts the translational reading frame after codon 184 (Ser185IlefsTer32), introducing 31 novel frameshifted amino acids followed by a premature stop codon at position 215. The resulting truncated 4-transmembrane polypeptide lacks TM5–TM7, misfolds, and is sequestered inside the endoplasmic reticulum (ER), where it also hetero-oligomerizes with wild-type CCR5 in heterozygotes (dominant-negative ER retention) to prevent surface transport.

Geographically, CCR5-Δ32 exhibits a steep north-to-south clinial gradient across Eurasia: allele frequency peaks at ~12% to 16% in Northern Europe and Baltic populations (~1% to 2% homozygosity), averages ~10% across European ancestry, and is virtually absent (<0.1%) in Indigenous East Asian, Sub-Saharan African, and Native American populations. Ancient DNA (aDNA) sequencing of Bronze Age and Neolithic European skeletons indicates that CCR5-Δ32 arose from a single mutation event >5,000 years ago and expanded under historical selective pressure from ancient pathogens (such as Variola smallpox or viral hemorrhagic fevers). However, CCR5 loss is not cost-free—it illustrates classic antagonistic pleiotropy (balancing selection): because CCR5 is required to traffic protective CD4⁺/CD8⁺ T cells and macrophages into the central nervous system during flavivirus infection, CCR5-Δ32 homozygotes suffer a 4- to 8-fold increased risk of symptomatic, neuroinvasive, and fatal West Nile virus (WNV) and tick-borne encephalitis.

Clinically, CCR5-Δ32 directly inspired two landmark interventions:

1. Maraviroc (Selzentry): An oral small-molecule negative allosteric modulator (NAM) that binds deep inside the 7TM pocket of CCR5 (Glu283^7.39, Tyr108^3.32, Trp248^6.48), locking ECL2 into a conformation unrecognizable by HIV-1 gp120.
2. Allogeneic CCR5-Δ32/Δ32 Hematopoietic Stem-Cell Transplantation (HSCT): Reconstituting the immune system of HIV-1 patients undergoing leukemia/lymphoma therapy with donor CCR5-Δ32/Δ32 CD34⁺ stem cells achieved the only verified sterilizing cures of HIV-1 in medical history (the Berlin, London, Düsseldorf, New York, and City of Hope patients).

ACE2 Metallopeptidase Recognition and TMPRSS2 S2′ Proteolytic Priming

For SARS-CoV-2 and SARS-CoV-1, host-cell entry into nasal ciliated epithelial cells (FOXJ1⁺) and alveolar type II (AT2) pneumocytes requires the coordinated action of two host plasma-membrane proteins:

1. Angiotensin-Converting Enzyme 2 (ACE2 on ChrXp22.2): An 805-amino-acid, zinc-dependent carboxypeptidase (M2 family) that physiologically cleaves vasoconstrictor angiotensin II (Ang II, 1–8) into vasodilatory, anti-fibrotic angiotensin-(1–7). Independent of its catalytic zinc active site, the N-terminal peptidase domain (PD) α1 and α2 helices (residues 19–83) and Lys353 β-hairpin of ACE2 form a high-affinity interface (K_d ≈ 1 to 15 nM) bound by the receptor-binding motif (RBM) of the SARS-CoV-2 Spike (S1) receptor-binding domain (RBD). Human population genetics (COVID-19 Host Genetics Initiative) identified a rare non-coding variant rs190509934 (T>C) just upstream of ACE2 that downregulates ACE2 transcription by 37% and reduces the risk of SARS-CoV-2 infection by 40% (OR ≈ 0.60), while rare coding variants (p.Lys26Arg enhancing affinity vs p.Ser19Pro/p.Glu37Lys weakening affinity) directly alter spike RBD binding kinetics.
2. Transmembrane Protease, Serine 2 (TMPRSS2 on Chr21q22.3): After SARS-CoV-2 Spike (which is pre-cleaved at its polybasic S1/S2 RRAR furin site in the producer cell Golgi) binds ACE2 on the target cell surface, the cell-surface trypsin-like serine protease TMPRSS2 (492 aa, containing an extracellular scavenger receptor cysteine-rich SRCR domain and a C-terminal His296–Asp345–Ser441 catalytic triad) cleaves the Spike S2 subunit at Arg815↓Ser816 (the S2′ site). This cleavage exposes the hydrophobic S2′ fusion peptide, driving rapid plasma-membrane fusion within <10 minutes (bypassing late endosomes and cathepsin L). Because TMPRSS2 expression is transcriptionally driven by an androgen response element (ARE) (the same promoter fused to ERG in ~50% of human prostate cancers), higher androgen-driven TMPRSS2 expression contributes to male predisposition in respiratory viral infections, while the common missense variant p.Val160Met (rs12329760) in the SRCR domain reduces proteolytic priming efficiency and protects against hospitalized COVID-19.

Remarkably, less than 500 kb centromeric to CCR5 on Chr3p21.31, genome-wide association studies discovered that the primary common host genetic risk factor for hypoxemic respiratory failure in COVID-19 (OR ≈ 1.6 to 2.1 per allele) is a 50-kb haplotype introgressed from Homo neanderthalensis (tagged by rs17713054 and rs11385942), where gain-of-function enhancer variants upregulate airway LZTFL1 (leucine zipper transcription factor-like 1, modulating ciliary antiviral response) and alter CXCR6 lung resident-memory T-cell recruitment.

When viruses lack TMPRSS2 cleavage at the cell surface—or when influenza A (H1N1, H3N2, H5N1), dengue, Ebola, or Omicron-lineage SARS-CoV-2 virions enter via clathrin-mediated endocytosis—membrane fusion takes place inside acidified late endosomes (pH 5.0–5.5). Guarding the endosomal membrane is interferon-induced transmembrane protein 3 (IFITM3), a 133-amino-acid protein encoded within the IFITM1–IFITM2–IFITM3–IFITM5 cluster on the subtelomere of chromosome 11p15.5. Upon Type I interferon (IFN-α/β) stimulation, IFITM3 is S-palmitoylated at three conserved cysteines (Cys71, Cys72, Cys105) and inserts an intramembrane amphipathic α-helix (residues 59–68) into the cytoplasmic leaflet of the endosomal lipid bilayer. This wedge-like insertion induces negative membrane curvature and increases lipid order (stiffness), trapping fusing influenza hemagglutinin (HA) or viral spikes at the outer-leaflet hemifusion stage so the fusion pore cannot open; trapped virions are then shuttled to lysosomes for degradation.

Two human polymorphisms cripple IFITM3 restriction:

1. rs12252 (c.42T>C in Exon 1): Although synonymous (p.Ser14=), the C allele (present at ~50%–55% allele frequency in East Asian populations vs ~4% in Europeans) was proposed to alter an exonic splicing enhancer or co-segregate with reduced functional endosomal IFITM3 localization; in Chinese and European cohorts during the 2009 H1N1 and H7N9 avian influenza pandemics, rs12252-C/C homozygotes exhibited a 4- to 6-fold higher risk of hospitalized influenza pneumonia and hypercytokinemia.
2. rs34481144 (C>T in the IFITM3 core promoter): Enriched in Europeans (MAF ≈ 25%–30%), the risk T allele disrupts binding of the activating transcription factor IRF3 while increasing occupancy of the chromatin insulator CTCF, reducing IFITM3 transcript abundance in CD8⁺ T cells and respiratory epithelium and increasing influenza mortality by ~2.6-fold.

How does the CCR5-Δ32 deletion protect heterozygotes (WT/Δ32) against HIV-1 progression even though they still have one normal copy of the CCR5 gene?

In WT/Δ32 heterozygotes, the CCR5 protein density on the surface of CD4⁺ T cells is often reduced by more than 50% (down to ~20%–35% of wild-type levels). This occurs because the truncated 215-amino-acid CCR5-Δ32 polypeptide is retained inside the endoplasmic reticulum (ER), where it hetero-dimerizes with wild-type CCR5 subunits (a dominant-negative trapping effect) and blocks their transport to the plasma membrane, slowing HIV-1 cell-to-cell spread and delaying AIDS onset by 2 to 4 years.

Why does SARS-CoV-2 require both ACE2 and TMPRSS2 for rapid entry into human airway epithelial cells?

ACE2 serves as the high-affinity attachment receptor (binding the Spike S1 receptor-binding domain), but binding ACE2 alone is insufficient to fuse the viral and host lipid membranes. Once ACE2 immobilizes the Spike trimer and exposes its internal S2′ cleavage loop (Arg815↓Ser816), the adjacent cell-surface serine protease TMPRSS2 must proteolytically cleave the S2′ site to unleash the hydrophobic fusion peptide, enabling direct plasma-membrane fusion within minutes.

How does IFITM3 block influenza A and coronavirus entry inside endosomes without binding to any specific viral protein?

Unlike antibodies or receptors that recognize a specific viral amino acid sequence, IFITM3 acts on the host endosomal lipid bilayer itself. Using three S-palmitoylated cysteines and a wedge-like amphipathic α-helix (residues 59–68), IFITM3 inserts into the cytosolic leaflet of the endosome, increasing membrane stiffness and inducing negative curvature. This raises the thermodynamic activation energy required to expand a lipid hemifusion stalk into a full fusion pore, trapping diverse enveloped viruses (influenza A, dengue, Ebola, coronaviruses) until the endosome fuses with degradative lysosomes.

1. Samson, M., Libert, F., Doranz, B. J., et al. (1996). "Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene." Nature, 382(6593), 722–725. https://doi.org/10.1038/382722a0
2. Hoffmann, M., Kleine-Weber, H., Schroeder, S., et al. (2020). "SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor." Cell, 181(2), 271–280. https://doi.org/10.1016/j.cell.2020.02.052
3. Everitt, A. R., Clare, S., Pertel, T., et al. (2012). "IFITM3 restricts the morbidity and mortality associated with influenza." Nature, 484(7395), 519–523. https://doi.org/10.1038/nature10921
4. Zeberg, H., & Pääbo, S. (2020). "The major genetic risk factor for severe COVID-19 is inherited from Neanderthals." Nature, 587(7835), 610–612. https://doi.org/10.1038/s41586-020-2818-3